# Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

> **NCT06489015** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Protgen Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** Recombinant Human Serum Albumin

## Key facts

- **NCT ID:** NCT06489015
- **Lead sponsor:** Protgen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06489015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06489015, "Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06489015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*